廣告
香港股市 已收市

  • 恒指

    17,718.61
    +2.14 (+0.01%)
     

  • 國指

    6,331.86
    +7.81 (+0.12%)
     

  • 上證綜指

    2,967.40
    +21.55 (+0.73%)
     

  • 滬深300

    3,461.66
    +7.54 (+0.22%)
     

  • 美元

    7.8080
    -0.0008 (-0.01%)
     

  • 人民幣

    0.9302
    -0.0001 (-0.01%)
     

  • 道指

    39,118.86
    -45.20 (-0.12%)
     

  • 標普 500

    5,460.48
    -22.39 (-0.41%)
     

  • 納指

    17,732.60
    -126.08 (-0.71%)
     

  • 日圓

    0.0483
    -0.0001 (-0.10%)
     

  • 歐元

    8.3628
    +0.0049 (+0.06%)
     

  • 英鎊

    9.8710
    +0.0020 (+0.02%)
     

  • 紐約期油

    81.46
    -0.28 (-0.34%)
     

  • 金價

    2,336.90
    +0.30 (+0.01%)
     

  • Bitcoin

    60,663.84
    -840.35 (-1.37%)
     

  • CMC Crypto 200

    1,264.88
    -18.95 (-1.48%)
     

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

Vandana Singh
·1 分鐘文章
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday.

Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS).

HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%).

The HARMONi-2 is a single-region, multi-center, double-blinded Phase 3 study conducted in China sponsored by Akeso Inc. with data generated and analyzed by Akeso.

廣告

At a prespecified interim analysis conducted by an independent Data Monitoring Committee, ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS by the blinded independent central radiology review committee (BICR) compared to Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab).

The progression-free survival (PFS) benefit was demonstrated across clinical subgroups, including those with PD-L1 low expression, PD-L1 high expression, squamous and non-squamous histologies, and other high-risk patients.

There are no known Phase 3 clinical trials in NSCLC that have shown a statistically significant improvement compared to pembrolizumab in a head-to-head setting.

Price Action: SMMT shares are down 28.60% at $7.80 at last check on Friday.

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.